retatrutide triple agonist glp-1 gip glucagon is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. Phase 2 trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Retatrutide is a next-generation triple-pathway

Looking for Solutions to Reduce Alcohol Abuse The new study points toward a new way to help reduce problematic alcohol use

Studies using exogenous oxidants such as tert -butyl hydroperoxide (tBH) and hydrogen peroxide (H 2 O 2 ) in cultured RPE cells highlight the role of oxidative stress in RPE cell death and premature senescence 8,9,10,11

Beyond these, the pipeline includes additional oral small molecules, once-monthly injectables, and further multi-agonist combinations

Measurable waist circumference reductions typically appear by week 1216

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus